YUKI GOSEI KOGYO CO.,LTD. Logo

YUKI GOSEI KOGYO CO.,LTD.

Manufactures fine chemicals, amino acids, and APIs via organic synthesis for global industries.

4531 | T

Overview

Corporate Details

ISIN(s):
JP3946400003
LEI:
Country:
Japan
Address:
中央区日本橋人形町三丁目10番4号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Yuki Gosei Kogyo Co., Ltd. is a chemical manufacturing company established in 1947. Specializing in the field of organic synthesis, the company engages in the research, development, manufacturing, and marketing of fine chemical products. Its core product portfolio includes amino acids (such as Glycine), pharmaceuticals, active pharmaceutical ingredients (APIs), and various chemical intermediates. Utilizing its unique and proprietary technologies, Yuki Gosei Kogyo serves both Japanese and international markets, providing high-quality products for various industrial applications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 02:35
Report Publication Announcement
確認書
Japanese 8.9 KB
2025-11-13 02:32
Interim Report
半期報告書-第106期(2025/04/01-2026/03/31)
Japanese 184.9 KB
2025-06-24 04:13
Post-Annual General Meeting Information
臨時報告書
Japanese 26.5 KB
2025-06-19 06:08
Governance Information
内部統制報告書-第105期(2024/04/01-2025/03/31)
Japanese 23.0 KB
2025-06-19 06:07
Registration Form
確認書
Japanese 8.8 KB
2025-06-19 06:05
Annual Report
有価証券報告書-第105期(2024/04/01-2025/03/31)
Japanese 724.5 KB
2025-01-08 02:05
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.8 KB
2024-12-04 02:01
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.8 KB
2024-11-13 02:17
Interim Report
確認書
Japanese 8.8 KB
2024-11-13 02:15
Interim Report
半期報告書-第105期(2024/04/01-2025/03/31)
Japanese 188.9 KB
2024-11-06 02:32
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.3 KB
2024-10-03 09:16
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.1 KB
2024-09-04 03:21
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.8 KB
2024-08-06 04:12
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.7 KB
2024-06-25 02:36
Post-Annual General Meeting Information
臨時報告書
Japanese 26.8 KB

Automate Your Workflow. Get a real-time feed of all YUKI GOSEI KOGYO CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for YUKI GOSEI KOGYO CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for YUKI GOSEI KOGYO CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Imunon, Inc. Logo
Developing DNA-based immunotherapies for oncology and infectious diseases.
United States of America
IMNN
IN8BIO, INC. Logo
Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.
United States of America
INAB
Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.
United Kingdom
INC
INCYTE CORP Logo
Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.
United States of America
INCY
Indaptus Therapeutics, Inc. Logo
Develops immunotherapies using engineered bacteria to treat cancer and viral infections.
United States of America
INDP
Indivior PLC Logo
Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.
United Kingdom
INDV
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden
IBT
InflaRx N.V. Logo
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America
IFRX
Inhibikase Therapeutics, Inc. Logo
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America
IKT
Inhibrx Biosciences, Inc. Logo
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America
INBX

Talk to a Data Expert

Have a question? We'll get back to you promptly.